Therefore, strategies to enhance PRDX1 activity, specifically in bone tissue, such as bone-targeted delivery systems, could maximize therapeutic benefits while minimizing systemic side effects, offering a promising avenue for the treatment of osteoporosis and other bone-related disorders. This evidence concerns the gene PRDX1 and osteoporosis.